Antiviral Efficacy of Pralatrexate against SARS-CoV-2
Biomolecules & Therapeutics
; : 268-272, 2021.
Article
en En
| WPRIM
| ID: wpr-889608
Biblioteca responsable:
WPRO
ABSTRACT
Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
En
Revista:
Biomolecules & Therapeutics
Año:
2021
Tipo del documento:
Article